Study title:
A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients.Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, Lemire J, Crocker JF, Cochat P, Clark G, Chodoff L, Korn A, Hall M.
Transplantation. 2002 Oct 15;74(7):961-6.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Immune System Diseases
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: Azathioprine |
ATC code: L04AX01 |
Document link:
|
Document date: 2015-03-03
|
Study number: PMID: 12394837
|
EudraCT number:
|
Scope of study: CLINICAL |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|